AXT's Rollercoaster Week: Leveraged ETFs, a $43.5M Lumentum Commitment, and the Battle Over Indium Phosphide's Future

AXT shares swing on indium phosphide shortage, prepayments from Lumentum, Coherent, and Casella, plus leveraged ETF launch and analyst skepticism.

The whiplash is the story. AXT shares swung from an 18% surge in mid-August to a two-day slide of nearly 20%, only to rebound again — a volatility profile that has attracted leveraged ETF issuers, heavyweight hedge funds, and a fresh wave of skeptical commentary from the sell side.

At the center of it all sits a California-based manufacturer of indium phosphide substrates, the critical raw material for optical components powering AI data centers. The company's second-quarter results, released roughly three weeks ago, laid bare the structural shift: indium phosphide revenue hit a record $30.7 million, representing nearly two-thirds of total sales of $47.6 million — a 77% jump quarter over quarter.

Supply Squeeze Meets Strategic Prepayments

The demand picture sharpened further on August 17, when a report from Taiwan's United Daily News pushed shares up 18% to $95.97. The catalyst: an acute supply shortage of indium phosphide substrates and epitaxial wafers, with price increases exceeding 10% planned for the fourth quarter — described as the largest jump ever recorded.

That scarcity is now translating into tangible commitments. Lumentum secured wafer capacity through a long-term supply agreement running through December 2031, backed by an initial prepayment of $43.5 million. AXT separately signed long-term supply contracts with China's Casella and U.S.-based Coherent during the second quarter, each carrying prepayments of $22.3 million and $25.4 million respectively.

These prepayments signal something beyond ordinary order confirmations — customers are willing to put cash down for guaranteed capacity, behavior more typical of scarce semiconductor precursors than second-tier substrate makers.

The Speculative Layer Builds

Where scarcity becomes narrative, speculation typically follows. On August 18, ETF provider Tradr launched four leveraged single-stock funds on AXT at the Cboe, including a 2x long variant and an inverse version offering daily -200% exposure. These products track trading volume, and AXT's has been extraordinary — its 30-day volatility of 184% now resembles cryptocurrency territory more than a substrate manufacturer with decades of history.

Institutional participation tells a mixed story. D. E. Shaw held roughly 2.25 million shares worth about $162 million as of June 30, Millennium Management accumulated 854,322 shares, and Balyasny opened a new position exceeding 114,000 shares. Meanwhile, director Leonard Leblanc sold shares worth approximately $605,000 in mid-August — a modest but notable counterpoint to institutional accumulation.

Skepticism Builds on the Margins

The pullback that followed the rally brought fresh criticism. Over two trading days ending August 25, the stock fell 10.5% and 9.3%, part of a sector-wide profit-taking wave that also dragged Lumentum, Coherent, and Applied Optoelectronics down between 5% and 6%. A Seeking Alpha contributor using the pseudonym "Bears of Wall Street" issued a Sell rating, citing an unattractive risk-reward profile after the market capitalization surge and questioning whether the company can execute flawlessly on capacity expansion and Chinese export permits.

Reports also circulated about a downgrade referencing the sustainability of the second quarter's robust 45% gross margin. Export license concerns — a recurring overhang for AXT — resurfaced to compound investor unease.

The analyst community remains divided. B. Riley Securities raised its price target to $55 from $52 while maintaining a Neutral stance; Needham upgraded from Hold to Buy. Both calls date from July 31, leaving them somewhat stale given subsequent price action.

A Stock in Discovery Mode

Technically, the picture has clouded. After the recent decline, shares traded 9.6% below their 50-day moving average of $56.13 — though the primary article notes a 4.5% gap and an RSI of 45, suggesting neither overbought nor oversold conditions. The stock appears to be in a price discovery phase, with the most recent session showing a 4.6% gain to €53.08.

Management is pressing its case on the conference circuit. After presenting at the Needham semiconductor conference on August 20, executives are scheduled for a B. Riley Securities event on September 10 and the Morgan Stanley Asia Best Corporate Day on September 21-22.

The central question for investors remains unchanged: is this a durable structural shift in indium phosphide demand, or a momentum story destined to fade as quickly as it flared? The prepayments from Lumentum, Casella, and Coherent argue for the former; the leveraged ETF debut, insider selling, and fresh sell-side skepticism argue for caution. The coming weeks of conference appearances may determine which narrative wins.